Genmab A/S (NASDAQ:GMAB) Receives “Outperform” Rating from BMO Capital Markets

Genmab A/S (NASDAQ:GMAB)‘s stock had its “outperform” rating reiterated by stock analysts at BMO Capital Markets in a research note issued on Friday,Benzinga reports. They presently have a $48.00 target price on the stock, up from their prior target price of $46.00. BMO Capital Markets’ price target would indicate a potential upside of 108.70% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Redburn Atlantic initiated coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th. Morgan Stanley restated an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, Truist Financial cut their price target on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB traded down $0.11 during midday trading on Friday, hitting $23.00. The company’s stock had a trading volume of 334,989 shares, compared to its average volume of 668,784. The stock has a market capitalization of $15.22 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 0.68 and a beta of 0.99. The stock’s 50 day simple moving average is $24.57 and its 200 day simple moving average is $26.47. Genmab A/S has a fifty-two week low of $21.90 and a fifty-two week high of $32.89.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The business had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. As a group, analysts anticipate that Genmab A/S will post 1.29 EPS for the current year.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently modified their holdings of the stock. Capital International Investors lifted its position in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after buying an additional 315,355 shares in the last quarter. Renaissance Technologies LLC grew its stake in Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after buying an additional 103,859 shares during the last quarter. DDD Partners LLC acquired a new position in Genmab A/S in the 2nd quarter valued at about $8,860,000. Cubist Systematic Strategies LLC grew its stake in Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after buying an additional 145,689 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its stake in Genmab A/S by 6.5% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after buying an additional 14,165 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.